Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
28.05. | AcouSort AB: AcouSort AB - Interim Report for the period January - March 2025 | 42 | GlobeNewswire (Europe) | The "Company" or "AcouSort" refers to AcouSort AB (publ) with corporate registration number 556824-1037.
First quarter 2025 for the GroupNet sales amounted to TSEK 1,595 (1,357)Result before tax amounted... ► Artikel lesen | |
09.04. | AcouSort AB: Bulletin from the Extraordinary General Meeting of AcouSort AB (publ) | 95 | GlobeNewswire (Europe) | The following resolutions were passed at the Extraordinary General Meeting (the "EGM") of AcouSort AB (publ) (the "Company") on 9 April 2025 in Lund.
Rights issue of sharesThe EGM resolved to approve... ► Artikel lesen | |
09.04. | XFRA CAPITAL ADJUSTMENT INFORMATION - 09.04.2025 | 140 | Xetra Newsboard | Das Instrument N7S CA87043J2039 SWEET POISON SPIRITS INC. EQUITY wird cum Kapitalmassnahme gehandelt am 09.04.2025 und ex Kapitalmassnahme am 10.04.2025 The instrument N7S CA87043J2039 SWEET POISON... ► Artikel lesen | |
26.03. | AcouSort AB: AcouSort's CEO answers questions about the company's rights issue and gives his view on the future | 134 | GlobeNewswire (Europe) | In connection with AcouSort's announcement of its plan to carry out a rights issue, several shareholders have contacted the company with questions regarding both the issue itself and how the management... ► Artikel lesen | |
19.03. | AcouSort AB: AcouSort in new collaboration to improve sepsis treatment | 186 | GlobeNewswire (Europe) | AcouSort's business strategy relies on early development collaborations to integrate its separation technology in partnering companies' products and systems. The most recent collaboration of this kind... ► Artikel lesen | |
03.03. | AcouSort AB: AcouSort and Bio-ReCell enter collaboration | 135 | GlobeNewswire (Europe) | AcouSort AB ("AcouSort") and Bio-ReCell Ltd ("Bio-ReCell") announce that the two companies have signed a Letter of Intent to jointly explore developing a system for automated clean-up and isolation... ► Artikel lesen | |
14.02. | AcouSort AB: Year end report for AcouSort AB 1 January - 31 December 2024 | 67 | GlobeNewswire (Europe) | The "Company" or "AcouSort" refers to AcouSort AB (publ) with corporate registration number 556824-1037
Fourth quarter for the GroupNet sales amounted to TSEK 1,221 (0)Result before tax amounted to... ► Artikel lesen | |
27.11.24 | AcouSort AB: AcouSort AB - Interim Report for the period July - September 2024 | 116 | GlobeNewswire (Europe) | Summary of the interim report
Significant events during the third quarterOn July 12, AcouSort announces that the Company and GenSensor will collaborate to combine AcouSort's acoustofluidics technology... ► Artikel lesen | |
ACOUSORT Aktie jetzt für 0€ handeln | |||||
28.08.24 | AcouSort AB: AcouSort AB - Interim Report for the period April - June 2024 | 94 | GlobeNewswire (Europe) | Summary of the report
Second quarter 2024 for the GroupNet sales amounted to TSEK 961 (1,816)Result before tax amounted to TSEK -4,714 (-3,193)Result per share* was SEK -0.32 (-0.24)Equity ratio** amounted... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
NOVONESIS | 64,32 | +0,22 % | dsm-firmenich completes sale of its stake in Feed Enzymes Alliance to Novonesis for €1.5 billion | Press Release
dsm-firmenich completes sale of its stake in Feed Enzymes Alliance to Novonesis for €1.5 billion
Kaiseraugst (Switzerland), Maastricht (Netherlands), June 2, 2025
dsm-firmenich... ► Artikel lesen | |
BIOCRYST PHARMACEUTICALS | 9,668 | -0,17 % | BioCryst Pharmaceuticals, Inc.: BioCryst Achieves Reimbursement for ORLADEYO Across all Major European Countries | RESEARCH TRIANGLE PARK, N.C., June 06, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that, following a positive recommendation from the Zorginstituut Nederland... ► Artikel lesen | |
SARTORIUS STEDIM BIOTECH | 191,95 | -0,83 % | Sartorius Stedim Biotech SA: Declaration Relative to the Number of Shares and Voting Rights Making up the Issued Capital | DJ Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA
Sartorius Stedim Biotech SA: DECLARATION... ► Artikel lesen | |
VBI VACCINES | 0,085 | 0,00 % | VBI Vaccines Inc/BC - 8-K, Current Report | ||
ADMA BIOLOGICS | 20,600 | +3,31 % | ADMA Stock Gains 17% in Three Months: Buy, Sell or Hold? | ||
GLYCOMIMETICS | 0,167 | -1,30 % | GlycoMimetics Stockholders Approve Proposed Merger with Crescent Biopharma and All Related Proposals | GlycoMimetics Board of Directors approves 1-for-100 reverse stock split
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) ("GlycoMimetics") today announced that its stockholders... ► Artikel lesen | |
BIOLIFE SOLUTIONS | 18,600 | -2,11 % | BioLife Solutions, Inc.: BioLife Solutions Reports First Quarter 2025 Financial Results | Cell Processing revenue of $21.6 million, up 33% over Q1 2024
GAAP gross margin of 63% and non-GAAP adjusted gross margin of 66%
GAAP net loss of $0.4 million and... ► Artikel lesen | |
PHATHOM PHARMACEUTICALS | 8,920 | +90,19 % | Phathom Pharmaceuticals Announces Positive FDA Decision to Recognize 10 Years of Regulatory Exclusivity for VOQUEZNA (vonoprazan) Tablets through May 3, 2032 | FLORHAM PARK, N.J., June 06, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT) today announced that the U.S. Food and Drug Administration (FDA) has approved Phathom's Citizen Petition... ► Artikel lesen | |
AVIDITY BIOSCIENCES | 36,240 | +1,83 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN DIEGO, May 21, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics... ► Artikel lesen | |
QIAGEN | 40,060 | -0,55 % | DEUTSCHE BANK RESEARCH stuft QIAGEN NV auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat das Kursziel für Qiagen von 47 auf 50 US-Dollar angehoben und die Einstufung auf "Buy" belassen. Analyst Jan Koch zog in seinem am Dienstag... ► Artikel lesen | |
ARCELLX | 68,10 | +2,81 % | Arcellx, Inc.: Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 | Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced... ► Artikel lesen | |
ARCUTIS BIOTHERAPEUTICS | 14,370 | +6,37 % | Arcutis Biotherapeutics, Inc.: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | WESTLAKE VILLAGE, Calif., June 06, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 5,485 | +20,02 % | Recursion Pharmaceuticals shares surge on AI model release | ||
TARSUS PHARMACEUTICALS | 43,920 | -0,39 % | Oppenheimer assumes Tarsus stock at outperform on strong sales | ||
BIONTECH | 95,35 | +0,05 % | Allianz gegen Krebs: BioNTech sichert sich Milliarden-Deal mit Bristol Myers: Aktie explodiert! | © Foto: picture alliance / Laci Perenyi | Laci PerenyiBioNTech erhält 1,5 Milliarden US-Dollar Vorschuss von Bristol Myers - für die gemeinsame Entwicklung eines vielversprechenden Krebswirkstoffs.... ► Artikel lesen |